Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker: A Role for Combination in Diabetic Nephropathy?

Steele A Whiteside C . Clinical practice guidelines for the management of diabetic nephropathy in Canada. Can J Diabetes Care 1999;23:53–61.

Canadian Organ Replacement Register. Preliminary statistics on renal failure and solid organ transplantation in Canada 2002. Ottawa: Canadian Institute for Health Information; 2003.

Lewis EJ Hunsicker LG Bain RP Rhode RD . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456–62. Erratum in: N Engl J Med 1993;330:152.

Mathiesen ER Hommel E Giese J Parving HH . Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991;303:81–7.

EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and nor-moalbuminuria or microalbuminuria. Lancet 1997;349:1787–92.

Viberti G Mogensen CE Groop LC Pauls JF . Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994;271:275–9.

Ravid M Savin H Jutrin I Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577–81.

Ravid M Brosh D Levi Z Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized controlled trial. Ann Intern Med 1998;128:982–8.

Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–9. Erratum in: Lancet 2000;356:860.

Brenner BM Cooper ME Zeeuw D Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9.

Lewis EJ Hunsicker LG Clarke WR Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60.

Parving HH Lehnert H Brochner-Mortensen J The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–8.

Briggs JP Kriz W Schnermann JB . Overview of renal function and structure. In: Greenberg A . Primer on kidney diseases. 2nd ed. San Diego: Academic Press; 1998:3–35.

Klahr S Morrissey J . Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage. Kidney Int 2002;62(Suppl 82):S23–6.

Canadian Diabetes Association. 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(2 Suppl):S1–151.

Canadian Hypertension Education Program. 2004 Canadian Hypertension Education Program Recommendations: the bottom line version. Available: http://chs.md/Documentation/CHEP2004_exec_summary.pdf (accessed August 13, 2004).

Bakris GL Williams M Dworkin L Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646–61.

Mogensen CE Neldam S Tikkanen I Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440–4.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–13. Erratum in BMJ 1999;318:29.

Jacobsen P Andersen S Jensen BR Parving HH . Additive effect of ACE inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992–9.

Rossing K Christensen PK Jensen BR Parving HH . Dual blockade of the renin—angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95–100.

Kincaid-Smith P Fairley K Packham D . Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002;17:597–601. Erratum in Nephrol Dial Transplant 2002;17:1153.

Jacobsen P Andersen S Rossing K Dual blockade of the renin—angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874–80.

Luno J Barrio V Goicoechea MA Effects of dual blockade of the renin—angiotensin system in primary proteinuric nephropathies. Kidney Int 2002;62(82 Suppl):S47–52.

Nakao N Yoshimura A Morita H Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117–24. Erratum in: Lancet 2003;361:1230.